Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report

Kazunobu Shinoda, Shinya Morita, Satoshi Tamaki, Ryohei Takahashi, Sotaro Kitaoka, Hiroshi Asanuma, Tadashi Yoshida, Mikio Okayama, Hidenori Kasahara, Shinichiro Okamoto, Mototsugu Oya

Research output: Contribution to journalArticle

Abstract

Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.

Original languageEnglish
Pages (from-to)604-607
Number of pages4
JournalTransplantation Proceedings
Volume52
Issue number2
DOIs
Publication statusPublished - 2020 Mar

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this